Collegium Pharmaceutical

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell COLL and other ETFs, options, and stocks.

About COLL

Collegium Pharmaceutical, Inc. is a pharmaceutical company, which engages in development and planning to commercialize next generation, abuse-deterrent products for the treatment of patients suffering from chronic pain and other diseases. Its products include Xtampza ER, Nucynta ER and Nucynta IR, Belbuca, and Symproic. 

CEO
Vikram Karnani
CEOVikram Karnani
Employees
423
Employees423
Headquarters
Stoughton, Massachusetts
HeadquartersStoughton, Massachusetts
Founded
2002
Founded2002
Employees
423
Employees423

COLL Key Statistics

Market cap
1.21B
Market cap1.21B
Price-Earnings ratio
18.51
Price-Earnings ratio18.51
Dividend yield
Dividend yield
Average volume
541.58K
Average volume541.58K
High today
$37.83
High today$37.83
Low today
$37.00
Low today$37.00
Open price
$37.80
Open price$37.80
Volume
66.77K
Volume66.77K
52 Week high
$50.79
52 Week high$50.79
52 Week low
$27.84
52 Week low$27.84

Stock Snapshot

The current Collegium Pharmaceutical(COLL) stock price is $37.32, with a market capitalization of 1.21B. The stock trades at a price-to-earnings (P/E) ratio of 18.51.

During the trading session on 2026-05-11, Collegium Pharmaceutical(COLL) shares reached a daily high of $37.83 and a low of $37.00. At a current price of $37.32, the stock is +0.9% higher than the low and still -1.3% under the high.

Trading volume for Collegium Pharmaceutical(COLL) stock has reached 66.77K, versus its average volume of 541.58K.

The stock's 52-week range extends from a low of $27.84 to a high of $50.79.

The stock's 52-week range extends from a low of $27.84 to a high of $50.79.

COLL News

TipRanks 4d
Collegium Reports Strong Q1 Results, Reaffirms 2026 Outlook

Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Discover top-performing stock ideas and upgrade to a portfolio of mark...

Simply Wall St 5d
What Collegium Pharmaceutical's Margin Pressure Ahead of Q1 2026 Earnings Means For Shareholders

Collegium Pharmaceutical, a specialty pain-medicine maker, is approaching its first-quarter 2026 earnings release on May 7, with Wall Street expecting earnings...

What Collegium Pharmaceutical's Margin Pressure Ahead of Q1 2026 Earnings Means For Shareholders

Analyst ratings

86%

of 7 ratings
Buy
85.7%
Hold
14.3%
Sell
0%

People also own

Based on the portfolios of people who own COLL. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.